Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Metagenomi, Inc. ( (MGX) ).
On September 29, 2025, Metagenomi, Inc. entered into a Non-Exclusive License Agreement with Acuitas Therapeutics, Inc. to utilize Acuitas’s lipid nanoparticle technology for developing and commercializing genome editing constructs. This agreement involves financial commitments, including maintenance fees, milestone payments, and royalties. The agreement can be terminated under specific conditions. On September 30, 2025, Metagenomi terminated its agreement with Affini-T Therapeutics, regaining full control over its intellectual property and manufacturing rights related to TCR-based therapeutic products, as Affini-T assigned its benefits to creditors. This termination allows Metagenomi to freely operate in previously restricted areas without future payments from Affini-T.
The most recent analyst rating on (MGX) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Metagenomi, Inc. stock, see the MGX Stock Forecast page.
Spark’s Take on MGX Stock
According to Spark, TipRanks’ AI Analyst, MGX is a Neutral.
Metagenomi, Inc. exhibits strong revenue growth and positive technical momentum, but faces significant challenges in profitability and cash flow management. The negative P/E ratio and lack of dividend yield highlight ongoing financial struggles. Investors should be cautious of liquidity risks despite the stock’s current upward trend.
To see Spark’s full report on MGX stock, click here.
More about Metagenomi, Inc.
Metagenomi, Inc. operates in the biotechnology industry, focusing on genome editing technologies. The company develops proprietary genome editing constructs and collaborates with partners to commercialize therapeutic products.
Average Trading Volume: 578,055
Technical Sentiment Signal: Buy
Current Market Cap: $86.33M
See more data about MGX stock on TipRanks’ Stock Analysis page.